These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

112 related articles for article (PubMed ID: 31767402)

  • 1. Discovery of N-ethylpyridine-2-carboxamide derivatives as a novel scaffold for orally active γ-secretase modulators.
    Sekioka R; Honda S; Honjo E; Suzuki T; Akashiba H; Mitani Y; Yamasaki S
    Bioorg Med Chem; 2020 Jan; 28(1):115132. PubMed ID: 31767402
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Optimization and biological evaluation of imidazopyridine derivatives as a novel scaffold for γ-secretase modulators with oral efficacy against cognitive deficits in Alzheimer's disease model mice.
    Sekioka R; Honda S; Akashiba H; Yarimizu J; Mitani Y; Yamasaki S
    Bioorg Med Chem; 2020 Jun; 28(11):115455. PubMed ID: 32307259
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Discovery of novel scaffolds for γ-secretase modulators without an arylimidazole moiety.
    Sekioka R; Honjo E; Honda S; Fuji H; Akashiba H; Mitani Y; Yamasaki S
    Bioorg Med Chem; 2018 Jan; 26(2):435-442. PubMed ID: 29249626
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Discovery of novel 5,6,7,8-tetrahydro[1,2,4]triazolo[4,3-a]pyridine derivatives as γ-secretase modulators.
    Takai T; Hoashi Y; Tomata Y; Morimoto S; Nakamura M; Watanabe T; Igari T; Koike T
    Bioorg Med Chem Lett; 2015 Oct; 25(19):4245-9. PubMed ID: 26298496
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pharmacological and Toxicological Properties of the Potent Oral
    Wagner SL; Rynearson KD; Duddy SK; Zhang C; Nguyen PD; Becker A; Vo U; Masliah D; Monte L; Klee JB; Echmalian CM; Xia W; Quinti L; Johnson G; Lin JH; Kim DY; Mobley WC; Rissman RA; Tanzi RE
    J Pharmacol Exp Ther; 2017 Jul; 362(1):31-44. PubMed ID: 28416568
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Design and synthesis of novel methoxypyridine-derived gamma-secretase modulators.
    Rynearson KD; Buckle RN; Herr RJ; Mayhew NJ; Chen X; Paquette WD; Sakwa SA; Yang J; Barnes KD; Nguyen P; Mobley WC; Johnson G; Lin JH; Tanzi RE; Wagner SL
    Bioorg Med Chem; 2020 Nov; 28(22):115734. PubMed ID: 33007551
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Design and synthesis of piperazine derivatives as a novel class of γ-secretase modulators that selectively lower Aβ₄₂ production.
    Takai T; Koike T; Honda E; Kajita Y; Nakamura M; Morimoto S; Hoashi Y; Kamata M; Watanabe T; Igari T; Terauchi J
    Bioorg Med Chem; 2015 May; 23(9):1923-34. PubMed ID: 25842363
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Discovery of novel 5,6,7,8-tetrahydro[1,2,4]triazolo[4,3-a]pyridine derivatives as γ-secretase modulators (Part 2).
    Takai T; Koike T; Nakamura M; Kajita Y; Yamashita T; Taya N; Tsukamoto T; Watanabe T; Murakami K; Igari T; Kamata M
    Bioorg Med Chem; 2016 Jul; 24(14):3192-206. PubMed ID: 27255179
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Discovery of γ-secretase modulators with a novel activity profile by text-based virtual screening.
    Zettl H; Ness J; Hähnke V; Beher D; Jumpertz T; Saric A; Baumann K; Pietrzik CU; Bulic B; Schneider G; Weggen S
    ACS Chem Biol; 2012 Sep; 7(9):1488-95. PubMed ID: 22725102
    [TBL] [Abstract][Full Text] [Related]  

  • 10. BIIB042, a novel γ-secretase modulator, reduces amyloidogenic Aβ isoforms in primates and rodents and plaque pathology in a mouse model of Alzheimer's disease.
    Scannevin RH; Chollate S; Brennan MS; Snodgrass-Belt PA; Peng H; Xu L; Jung MY; Bussiere T; Arastu MF; Talreja T; Xin Z; Dunstan RW; Fahrer D; Rohde E; Dunah AW; Wang J; Kumaravel G; Taveras AG; Moore Arnold H; Rhodes KJ
    Neuropharmacology; 2016 Apr; 103():57-68. PubMed ID: 26690893
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pharmacological properties of a novel and potent γ-secretase modulator as a therapeutic option for the treatment of Alzheimer's disease.
    Murakami K; Watanabe T; Koike T; Kamata M; Igari T; Kondo S
    Brain Res; 2016 Feb; 1633():73-86. PubMed ID: 26707977
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Characterization of FRM-36143 as a new γ-secretase modulator for the potential treatment of familial Alzheimer's disease.
    Blain JF; Bursavich MG; Freeman EA; Hrdlicka LA; Hodgdon HE; Chen T; Costa DE; Harrison BA; Kapadnis S; Murphy DA; Nolan S; Tu Z; Tang C; Burnett DA; Patzke H; Koenig G
    Alzheimers Res Ther; 2016 Aug; 8(1):34. PubMed ID: 27572246
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Orally bioavailable and brain-penetrant pyridazine and pyridine-derived γ-secretase modulators reduced amyloidogenic Aβ peptides in vivo.
    Huang Y; Li T; Eatherton A; Mitchell WL; Rong N; Ye L; Yang XJ; Jin S; Ding Y; Zhang J; Li Y; Wu Y; Jin Y; Sang Y; Cheng Z; Browne ER; Harrison DC; Hussain I; Wan Z; Hall A; Lau LF; Matsuoka Y
    Neuropharmacology; 2013 Jul; 70():278-86. PubMed ID: 23485401
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pharmacological characterization of the novel γ-secretase modulator AS2715348, a potential therapy for Alzheimer's disease, in rodents and nonhuman primates.
    Mitani Y; Akashiba H; Saita K; Yarimizu J; Uchino H; Okabe M; Asai M; Yamasaki S; Nozawa T; Ishikawa N; Shitaka Y; Ni K; Matsuoka N
    Neuropharmacology; 2014 Apr; 79():412-9. PubMed ID: 24373902
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Soluble Gamma-secretase Modulators Attenuate Alzheimer's β-amyloid Pathology and Induce Conformational Changes in Presenilin 1.
    Raven F; Ward JF; Zoltowska KM; Wan Y; Bylykbashi E; Miller SJ; Shen X; Choi SH; Rynearson KD; Berezovska O; Wagner SL; Tanzi RE; Zhang C
    EBioMedicine; 2017 Oct; 24():93-101. PubMed ID: 28919280
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Combining an amyloid-beta (Aβ) cleaving enzyme inhibitor with a γ-secretase modulator results in an additive reduction of Aβ production.
    Strömberg K; Eketjäll S; Georgievska B; Tunblad K; Eliason K; Olsson F; Radesäter AC; Klintenberg R; Arvidsson PI; von Berg S; Fälting J; Cowburn RF; Dabrowski M
    FEBS J; 2015 Jan; 282(1):65-73. PubMed ID: 25303711
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Discovery of 2-methylpyridine-based biaryl amides as γ-secretase modulators for the treatment of Alzheimer's disease.
    Chen JJ; Qian W; Biswas K; Yuan C; Amegadzie A; Liu Q; Nixey T; Zhu J; Ncube M; Rzasa RM; Chavez F; Chen N; DeMorin F; Rumfelt S; Tegley CM; Allen JR; Hitchcock S; Hungate R; Bartberger MD; Zalameda L; Liu Y; McCarter JD; Zhang J; Zhu L; Babu-Khan S; Luo Y; Bradley J; Wen PH; Reid DL; Koegler F; Dean C; Hickman D; Correll TL; Williamson T; Wood S
    Bioorg Med Chem Lett; 2013 Dec; 23(23):6447-54. PubMed ID: 24139583
    [TBL] [Abstract][Full Text] [Related]  

  • 18. γ-Secretase modulator in Alzheimer's disease: shifting the end.
    Xia W; Wong ST; Hanlon E; Morin P
    J Alzheimers Dis; 2012; 31(4):685-96. PubMed ID: 22710916
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cholestenoic acid, an endogenous cholesterol metabolite, is a potent γ-secretase modulator.
    Jung JI; Price AR; Ladd TB; Ran Y; Park HJ; Ceballos-Diaz C; Smithson LA; Hochhaus G; Tang Y; Akula R; Ba S; Koo EH; Shapiro G; Felsenstein KM; Golde TE
    Mol Neurodegener; 2015 Jul; 10():29. PubMed ID: 26169917
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Robust Translation of γ-Secretase Modulator Pharmacology across Preclinical Species and Human Subjects.
    Toyn JH; Boy KM; Raybon J; Meredith JE; Robertson AS; Guss V; Hoque N; Sweeney F; Zhuo X; Clarke W; Snow K; Denton RR; Zuev D; Thompson LA; Morrison J; Grace J; Berisha F; Furlong M; Wang JS; Lentz KA; Padmanabha R; Cook L; Wei C; Drexler DM; Macor JE; Albright CF; Gasior M; Olson RE; Hong Q; Soares HD; AbuTarif M; Ahlijanian MK
    J Pharmacol Exp Ther; 2016 Jul; 358(1):125-37. PubMed ID: 27189974
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.